Jobs

27-04-22 - Biomedical Sciences

GMP Production Operator 100 %

The Wyss Zurich Project LifeMatrix develops and manufactures tissue-engineered human matrices to repair and regenerate the heart. The multidisciplinary team has developed a unique tissue engineering technology to grow replacement tissue in the laboratory, which will be compatible with every patient, regenerate and grow with the recipient. Your responsibilities will include the production of our next generation-biomimetic implants for clinical use. You will be working in the clean room facilities (GMP class B / ISO 5) of the Wyss Zurich located at Moussonstrasse in the heart of the university district. You have a supportive role in the transition of our technology from R&D to manufacturing by driving optimization and harmonization of the GMP and ISO-13485 processes.

read more

27-04-22 - Biomedical Sciences

GMP Scientist 60-100 %

LifeMatrix is part of the Wyss Zurich Translational Center since 2015. LifeMatrix is active in the fast-growing field of medical biomimetics and has developed a unique tissue engineering technology to grow human replacement tissues in the laboratory as next-generation implants for the treatment of cardiovascular diseases. The LifeMatrix technology has the potential to overcome the significant limitations of existing implants and revolutionize the medical device industry. The team is now seeking a GMP Scientist (60-100%) and is offering a unique opportunity to become part of a multidisciplinary startup team of young scientists, world-leading tissue engineering experts, and entrepreneurs who share the vision of helping children with a congenital heart defect live better lives.

read more

30-03-22 - Biomedical Sciences

Produktionsoperator/Laborant/in – pharmazeutisches Umfeld 100%

The Somagenetix project at Wyss Zurich has an opening for a Production Operator / Lab Technician to assist in the development of a gene therapy for children with primary immunodeficiency. As a member of the production team you will make an important contribution to the GMP-compliant production of genetically modified human hematopoietic stem cells for phase I/II clinical trials.

read more